Seegene posts W136b in Q2 sales as operating profit surges 586%

Seegene, a global molecular diagnostics company, posted strong second-quarter earnings, with broad-based growth in its non-respiratory product lines driving a sharp improvement in sales and operating profit.

The company announced Friday that its preliminary consolidated results for the second quarter of 2026 showed sales of 136 billion won ($95.9 million), operating profit of 21.6 billion won and net profit for the period of 26 billion won. Compared with the same period a year earlier, sales rose 19.2% and operating profit surged 586.4%, while the company returned to net profit after a loss in the prior-year period.

The strong results came despite the seasonal off-peak period for respiratory diagnostics, as non-respiratory product lines — including human papillomavirus (HPV), sexually transmitted infection (STI) and gastrointestinal (GI) tests — posted double-digit growth.

By product category, HPV product sales rose 40.3% year on year, STI products gained 20.7% and GI products climbed 13.9%. Non-respiratory products as a whole grew 22.9% from a year earlier, cementing their role as a stable growth pillar that offsets the higher seasonal volatility of the respiratory segment. By region, Europe accounted for the largest share of sales at 57.2%, followed by Asia at 19.1%, Latin America at 12.4%, South Korea at 6.4% and North America at 4.9%.

Seegene has been moving away from a single-disease diagnostic model sensitive to seasonal swings, diversifying into high-margin non-respiratory products and expanding overseas sales to more than 90% of total revenue — a strategy the company says reshapes its business around higher-value, more stable growth.

The company is also pressing ahead to secure future growth drivers. In July, it unveiled STAgora, a statistical platform for PCR data analysis, and CURECA, a fully automated end-to-end system, at the Association for Diagnostics & Laboratory Medicine (ADLM 2026) conference in the United States. Starting this month, Seegene is launching its Global Million Clinical Study targeting medical institutions worldwide, aiming to establish new global testing standards based on syndromic PCR.

"As non-respiratory products have cemented their position as a key growth pillar, we have been able to sustain sales growth and improve profitability," said Kim Jeong-yong, Seegene's chief financial officer. "We will continue investing in future growth foundations — including STAgora and CURECA — and in new product development to further solidify our medium- to long-term growth base."